Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

Next Previous
Trial Profile

A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonpiretigene isteparvovec (Primary)
  • Indications Retinitis pigmentosa
  • Focus Registrational; Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Nanoscope Therapeutics

Most Recent Events

  • 26 Aug 2025 According to a Nanoscope Therapeutics media release, the company will present compelling new data from its RESTORE long-term follow-up study, REMAIN, at the 2025 Euretina Congress and Retina Society Annual Scientific Meeting
  • 14 Jul 2025 According to a Nanoscope Therapeutics media release, a rolling BLA submission to the FDA has been initiated following positive results from this study. The FDA has granted Nanoscope rolling review of its BLA, with the first modules already submitted and full BLA submission anticipated in early 2026. It is eligible for priority review under fast-track designation.
  • 31 Oct 2024 According to a Nanoscope Therapeutics media release, positive 2-year results from the Phase 2b RESTORE were presented by Allen C. Ho, MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope, on October 20, 2024 at the recently concluded AAO 2024 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top